StarTek ( SRT) fell after the Denver-based staffing-services company said fourth-quarter earnings will probably range between $1 million and $1.3 million, or 7 cents to 9 cents a share -- less than a third of year-ago income, which had totaled $4.4 million, or 30 cents a share. Revenue is expected at $59 million, up slightly from a year ago but falling about $5.8 million short of the Street projection. StarTek says the disappointing profits stem from lower gross margins that, at about 14%, represent a 7.6-point decline from last year. Shares were receding $2.49, or 19.5%, to $10.25. Coley Pharmaceutical ( COLY) slumped on news that the company will halt developing its hepatitis C drug candidate, Actilon, after a midphase study yielded unpromising results. The Wellesley, Mass., company will now focus on developing drugs that stimulate certain toll-like receptors (naturally occurring proteins that play a part in the immune system) for a product line called TLR Therapeutics. Shares were losing $1.14, or 11.5%, to $8.75.